Skip to main content
. 2017 Aug 2;9(8):1885–1897. doi: 10.18632/aging.101271

Figure 5. MiR‐338 inhibited tumor growth in vivo and prolonged the survival period.

Figure 5

(A) Luminescence imaging for miR‐338‐ treated U87‐luc tumors versus miR‐Scr‐treated controls (P<0.01, P<0.01, P<0.05, respectively). Kaplan‐Meier survival curves indicating that outcomes were significantly better in mice transfected with miR‐338 than in mice transfected with miR‐Scr (P<0.01). (B) IHC staining revealed that PKM2 and β‐catenin protein levels were lower in the miR‐338‐treated group than in the miR‐Scr‐treated group.